Lixte Biotechnology Cash Over Time

LIXT Stock  USD 1.21  0.01  0.83%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lixte Biotechnology Performance and Lixte Biotechnology Correlation.
  
At this time, Lixte Biotechnology's Cash is comparatively stable compared to the past year. Cash And Short Term Investments is likely to gain to about 5.1 M in 2025, whereas Other Cashflows From Financing Activities is likely to drop 6,907 in 2025.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.73)
Return On Assets
(0.72)
Return On Equity
(1.27)
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Cash Analysis

Compare Lixte Biotechnology and related stocks such as Allarity Therapeutics, NRBO Old, and Hillstream Biopharma Cash Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
2010201120122013201420152016201720182019202020212022202320242025
ALLR1.5 M1.5 M1.5 M1.5 M1.5 M1.5 M1.5 M1.5 M1.5 M1.5 M298 K19.6 MM166 K149.4 K141.9 K
VRAX22.6 K22.6 K22.6 K22.6 K22.6 K22.6 K22.6 K22.6 K22.6 K22.6 K17.6 K21.8 K9.4 M3.6 M4.1 M2.9 M
QNRX1.6 M1.6 M1.6 M1.6 M1.6 M1.6 M1.6 M6.3 M13.7 M5.2 M323.8 K7.5 M2.9 M2.4 M3.6 B3.8 B
INDP9.3 M9.3 M9.3 M9.3 M9.3 M9.3 M9.3 M9.3 M9.3 M9.3 M1.6 M39.1 M9.6 M13.4 M5.8 M10.5 M
KTTA243.7 K243.7 K243.7 K243.7 K243.7 K243.7 K243.7 K243.7 K243.7 K243.7 K243.7 K53 M33.1 M16.3 M18.8 M28.2 M
BDRX133 K133 K133 K2.4 M30.3 M16.2 M17.6 M13.2 M2.3 M10.9 M7.5 M10.1 M2.8 MM5.4 MM
PMVP30.3 M30.3 M30.3 M30.3 M30.3 M30.3 M30.3 M30.3 M30.3 M73.3 M361.4 M172.5 M108.3 M37.7 M40.9 M38.8 M
OLMA3.1 M3.1 M3.1 M3.1 M3.1 M3.1 M3.1 M3.1 M3.1 M68 K338.5 M287.2 M23.7 M68.5 M78.8 M132.2 M
SRRK10 M10 M10 M10 M10 M10 M10 M56.5 M115.1 M36.3 M160.4 M212.8 M103.3 M101.9 M177.9 M119.1 M
PASG24.9 M24.9 M24.9 M24.9 M24.9 M24.9 M24.9 M24.9 M24.9 M158.9 M135 M129 M34.6 M21.7 M37.6 M61.9 M

Lixte Biotechnology and related stocks such as Allarity Therapeutics, NRBO Old, and Hillstream Biopharma Cash description

Cash refers to the most liquid asset of Lixte Biotechnology, which is listed under current asset account on Lixte Biotechnology Holdings balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Lixte Biotechnology customers. The amounts must be unrestricted with restricted cash listed in a different Lixte Biotechnology account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

My Equities

My Current Equities and Potential Positions

Lixte Biotechnology Holdings
LIXT
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationNew York; U.S.A
ExchangeNASDAQ Exchange
USD 1.21

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.